Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
After treatment of mice bearing Ehrlich ascites tumor (EAT) with titanocene dichloride, it could be shown (a) that all cured animals were able to reject EAT cells implanted subsequently and (b) that in the serum of these animals the contents of gamma-globulins was markedly increased, whereas after treatment with cis-platinum both the ability to reject EAT cells and the increase of gamma-globulins were less pronounced. It is supposed that the observed increase of gamma-globulins is due to a stimulated production of antibodies against EAT.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000276:immunology; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D051379:Mice; D009942:Organometallic Compounds / Q000627:therapeutic use*; D014025:Titanium / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D014025:Titanium; C020528:titanocene dichloride; D002945:Cisplatin